Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 3, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging technique called the CEST sequence to see if it can effectively diagnose radionecrosis, a condition where brain tissue is damaged after radiation therapy for lung cancer. Researchers want to find out if this new method is just as good as the standard imaging technique currently used, which involves a special type of MRI with contrast dye. The goal is to improve how doctors identify and understand changes in brain metastases, which are cancerous growths that have spread to the brain from lung cancer.
To participate in this study, individuals must be over 18 years old, have a confirmed diagnosis of lung cancer, and have received radiation treatment for their brain metastases. They should also have experienced changes in their brain lesions as seen on follow-up MRI scans. Participants will undergo imaging tests to help researchers compare the new method with the standard approach. It’s important to know that individuals who cannot undergo MRI scans or who have severe cognitive impairments that prevent them from giving consent will not be eligible to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients \> 18 years of age
- • Histologically proven primary lung cancer
- • Histologically proven or not brain metastases
- • Irradiated metastases
- • Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy
- • Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI
- • Patients affiliated to a social security scheme
- Exclusion Criteria:
- • Opposition to the study
- • Contraindication to MRI
- • Refusal of imaging by the patient
- • Patient with state medical aid (unless exemption from affiliation)
- • Severe cognitive impairment making informed consent impossible
- • Patients under guardianship or deprived of liberty
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Augustin Gaudemer, MD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported